<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Jaguar Health Announces a Special One-time Stock Dividend</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Jaguar Health Announces a Special One-time Stock Dividend</h1>

    <table>
      <tr><th>Ticker</th><td>JAGX</td></tr>
      <tr><th>Float</th><td>2.2 M</td></tr>
      <tr><th>IO</th><td>1.41%</td></tr>
      <tr><th>MC</th><td>2.3 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Jaguar Health (NASDAQ: JAGX) announced its Board declared a one-time Special Stock Dividend payable March 4, 2026 to holders of common stock and certain warrants of record on March 2, 2026. The dividend will consist of Series O Convertible Preferred Stock, which the Company may convert into common stock at its election (or which will automatically convert on December 31, 2026 if not earlier converted). Conversion will be based on the market price of the common stock at the time. The Preferred Stock is non-transferable and will not be listed or tradable. The company says the dividend is intended to provide dilution protection to shareholders while it explores pathways to repay or restructure existing indebtedness; Jaguar referenced an 8-K filed February 18, 2026 for additional terms. The release also highlights recent non-dilutive licensing with Future Pak and ongoing clinical development of crofelemer with a target NDA filing for MVID in H1 2027.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Board declared one-time Special Stock Dividend to common stockholders and certain warrant holders (record date March 2, 2026; payment date March 4, 2026).</li><li>Dividend structured as Series O Convertible Preferred Stock that could provide holders protection against immediate dilution depending on conversion timing.</li><li>Company obtained non-dilutive capital via a January 2026 U.S. license agreement with Future Pak, per the release.</li><li>Ongoing crofelemer development with reported clinical benefit in an initial pediatric MVID patient and planned NDA filing for MVID in H1 2027.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Preferred Stock converts (by election or automatically on December 31, 2026) into common stock, which will result in issuance of common shares and potential dilution.</li><li>Preferred Stock is non-transferable and will not be listed or tradable.</li><li>Company is exploring debt repayment/restructuring, indicating outstanding indebtedness and related financial uncertainty.</li><li>No assurance of future dividends; forward-looking statements subject to risks and uncertainties.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/c20e9fe8-381b-4cec-b03b-7134c89a0629" target="_blank">Original Article</a>
    </div>

    <div class="small">JAGX â€¢ TradersLink AI News</div>
  </div>
</body>
</html>